



COMPANY OVERVIEW

AIM ImmunoTech Inc. (NYSE American: AIM) is an immuno-pharma company focused on researching and developing therapeutics to treat multiple types of cancers, immune disorders, and viral diseases. Their lead product candidate, Ampligen® (rintatolimod), is a first-in-class investigational drug that has demonstrated broad-spectrum activity in clinical trials for globally significant cancers, viral diseases, and immune system disorders. The company has an extensive pipeline across various high-value disease areas and collaborates with renowned university partners to fund most of its ongoing clinical studies. AIM ImmunoTech's management team comprises proven industry experts dedicated to advancing the company's programs and delivering results.

KEY CONSIDERATIONS

- Lead asset Ampligen® is being evaluated in multiple clinical trials across various indications.
- Broad pipeline targeting high-value disease areas, including immuno-oncology, immune disorders, and viral diseases.
- Promising data demonstrating Ampligen's potential in hard-to-treat cancers and conditions.
- Collaborations with prestigious university partners to fund clinical development.
- Well-developed safety profile with ~100,000 IV doses administered in humans.
- A strong cash position is expected to fund operations through multiple key milestones.

NYSEAMERICAN: AIM



AIM IMMUNOTECH

ADVANCING AMPLIGEN® FOR MULTIPLE INDICATIONS

Leveraging the Potential of a First-in-Class Investigational Immunotherapy

REPROGRAMMING THE TUMOR MICROENVIRONMENT

AIM's lead asset, Ampligen, is designed to potentially enhance the efficacy of cancer immunotherapies.

SYNERGISTIC EFFECTS WITH CHECKPOINT INHIBITORS

Ampligen may synergistically improve outcomes when combined with checkpoint inhibitors like Keytruda and Imfinzi.

TARGETING SIGNIFICANT UNMET NEEDS

AIM is developing Ampligen for cancers with high mortality and limited treatment options such as pancreatic, ovarian, and advanced recurrent cancers,

EXPERIENCED MANAGEMENT TEAM

AIM's leadership team brings decades of combined experience in drug development, clinical research, and corporate strategy.

ONGOING CLINICAL TRIALS

The company has multiple active clinical programs, including trials in advanced recurrent ovarian cancer, metastatic pancreatic cancer, and post-COVID conditions.

INTELLECTUAL PROPERTY PROTECTION

AIM has a robust IP portfolio with 46 patents worldwide and 72 pending applications, providing potential market exclusivity for Ampligen.

PIONEERING IMMUNOTHERAPIES TO TRANSFORM PATIENT OUTCOMES

AIM ImmunoTech is dedicated to developing novel immunotherapies that harness the immune system's power to fight cancer, viral infections, and immune disorders. The company's lead product candidate, Ampligen, is a first-in-class, investigational TLR3 agonist that has demonstrated broad-spectrum activity in clinical trials for various cancers, viral diseases, and immune system disorders. By targeting the early drivers of disease and selectively modulating the immune response, AIM aims to interrupt disease progression and restore immune homeostasis.

One of AIM's primary focus areas is immuno-oncology, where Ampligen has shown promising results in reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies. Preclinical and early clinical data suggest that Ampligen can convert immunologically "cold" tumors, which are unresponsive to checkpoint blockade, into "hot" tumors that are more susceptible to immune attack.

AIM is currently evaluating Ampligen in multiple clinical trials for hard-to-treat cancers with significant unmet medical needs. These include a Phase 2 study in advanced, recurrent ovarian cancer, a Phase 1b/2 trial in metastatic pancreatic cancer, and a planned Phase 2 study in locally advanced pancreatic cancer.

Beyond oncology, AIM is also investigating Ampligen as a potential treatment for chronic fatigue syndrome (CFS/ME) and post-COVID conditions. The drug has shown promising results in a Phase 3 study for CFS/ME, demonstrating significant improvement in exercise tolerance, and has received approval in Argentina for treating severe CFS/ME.

AIM ImmunoTech's experienced management team, led by CEO Thomas K. Equels, is well-positioned to advance the company's mission and create value for patients and shareholders. With a robust intellectual property portfolio, multiple ongoing clinical trials, and a promising pipeline of indications, AIM is poised for significant growth in the rapidly evolving field of immunotherapy.

~100,000

IV doses administered

46

Patents Worldwide

55%

Clinical Benefit Rate in ovarian cancer trial

19 MONTHS

Median Overall Survival in Pancreatic Cancer

NYSEAMERICAN: AIM



LEADERSHIP



THOMAS K. EQUELS, JD
CHIEF EXECUTIVE OFFICER

- APPOINTED CEO IN 2016 WITH OVER 25 YEARS OF EXPERIENCE IN BANKING, INSURANCE, AVIATION, PHARMACEUTICAL, AND CONSTRUCTION MATTERS
- SERVED AS PRESIDENT AND MANAGING DIRECTOR OF THE EQUELS LAW FIRM IN MIAMI, FLORIDA
- DECORATED MILITARY PILOT, AWARDED TWO DISTINGUISHED FLYING CROSSES, THE BRONZE STAR, THE PURPLE HEART, AND FIFTEEN AIR MEDALS



DAVID R. STRAYER, MD
MEDICAL OFFICER

- APPOINTED CHIEF SCIENTIFIC OFFICER IN 2016 AND HAS SERVED AS MEDICAL DIRECTOR SINCE 1986
- CONSIDERED THE FOREMOST MEDICAL EXPERT ON AMPLIGEN AND ALFERON WORLDWIDE
- BOARD CERTIFIED IN MEDICAL ONCOLOGY AND INTERNAL MEDICINE WITH RESEARCH INTERESTS IN CANCER AND IMMUNE SYSTEM DISORDERS



PETER W. RODINO III, JD
CHIEF OPERATING OFFICER, GENERAL COUNSEL, SECRETARY

- ASSUMED THE ROLE OF CHIEF OPERATING OFFICER IN 2019 AND HAS BEEN AIM'S SECRETARY SINCE 2016
- SERVED AS CHAIRMAN AND CEO OF CROSSROADS HEALTH PLAN, THE FIRST MAJOR HEALTH MAINTENANCE ORGANIZATION IN NEW JERSEY
- HOLDS A B.S. IN BUSINESS ADMINISTRATION FROM GEORGETOWN UNIVERSITY AND A J.D. DEGREE FROM SETON HALL UNIVERSITY



ROBERT DICKEY IV, MBA
CHIEF FINANCIAL OFFICER

- APPOINTED CFO IN 2022 WITH MORE THAN 25 YEARS OF EXPERIENCE IN C-SUITE FINANCIAL LEADERSHIP
- SERVED AS MANAGING DIRECTOR AT FORESITE ADVISORS AND DANFORTH ADVISORS, PROVIDING FINANCIAL SUPPORT AND INVESTMENT ADVISORY
- MBA FROM THE WHARTON SCHOOL AND AN AB FROM PRINCETON UNIVERSITY



CHRISTOPHER MCALEER, PHD
SCIENTIFIC OFFICER

- JOINED AIM IMMUNOTECH IN 2022 AND WAS PROMOTED TO SCIENTIFIC OFFICER IN DECEMBER 2022
- PREVIOUSLY HELD POSITIONS AT HESPEROS, INC.
- DOCTORATE IN BIOMEDICAL SCIENCES FROM THE UNIVERSITY OF CENTRAL FLORIDA AND COMPLETED POSTDOCTORAL RESEARCH AT THE SAME INSTITUTION